Please assess the completion status of the following clinical trial:

Trial Title: Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is a first-time recipient of a kidney transplant from a deceased donor.~* Specific donor criteria~Exclusion Criteria:~* Donor age \<10 years~* Subjects receiving a concurrent solid organ or cell transplant (lung, heart, etc.)~* Subjects with a positive T-cell lymphocytotoxic crossmatch.~* Subjects who are positive for Hepatitis B or C, or HIV~* Active tuberculosis~* History of cancer in the last 5 years~* History of substance abuse~* Specific laboratory results are exclusionary~* Mammography suspicious for cancer~* Allergy to iodine~* For Long-term extension study-Subjects who have completed three years of study treatment (through Week 156)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cyclosporin A (Type: ACTIVE_COMPARATOR): None
- Belatacept Less Intensive Regimen (LI) (Type: EXPERIMENTAL): None
- Belatacept More Intensive Regimen (MI) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).